Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Chief Operating Officer | March 12, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date March 12, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,343 |
Ending reported balance
After 2026-03-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-12 · Exercise / conversion · Acquired 26,101 · Balance 80,624 F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Row 2 · 2026-03-12 · Tax withholding · Disposed 13,281 · Balance 67,343 F2: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,101 |
Reported balance
After 2026-03-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-12 · Exercise / conversion · Disposed 26,101 · Balance 26,101 F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
F2: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2026 Filed Mar 16, 2026 18:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 26,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-108071 · ownership.xml · derivative · entry 3 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,101 Underlying: Common Stock · 26,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 18:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 13,281 | $11.53 | $153,129.93 |
DisclosureSEC source: 0001193125-26-108071 · ownership.xml · nonDerivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,343 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 18:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 26,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-108071 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:57 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 13,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-100329 · ownership.xml · derivative · entry 3 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:57 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 7,036 | $10.00 | $70,360.00 |
DisclosureSEC source: 0001193125-26-100329 · ownership.xml · nonDerivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,523 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:57 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 13,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-100329 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:25 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 6,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-094034 · ownership.xml · derivative · entry 3 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,568 Underlying: Common Stock · 6,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:25 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 3,380 | $8.84 | $29,879.20 |
DisclosureSEC source: 0001193125-26-094034 · ownership.xml · nonDerivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,732 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:25 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 6,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-094034 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:13 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 36,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059398 · ownership.xml · derivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,818 Underlying: Common Stock · 36,818 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029. F2 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:55 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 386 | $9.57 | $3,694.02 |
DisclosureSEC source: 0001193125-26-002973 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,470 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:28 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 7,480 | $26.11 | $195,302.80 |
DisclosureSEC source: 0001193125-25-239059 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,084 F1 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 21:08 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 361 | $10.15 | $3,664.15 |
DisclosureSEC source: 0000950170-25-093170 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,564 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 13,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-039521 · ownership.xml · derivative · entry 3 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,202 Underlying: Common Stock · 13,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 6,627 | $13.18 | $87,343.86 |
DisclosureSEC source: 0000950170-25-039521 · ownership.xml · nonDerivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,203 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 13,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-039521 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:50 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 13,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036673 · ownership.xml · derivative · entry 3 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,827 Underlying: Common Stock · 13,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:50 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 7,022 | $13.19 | $92,620.18 |
DisclosureSEC source: 0000950170-25-036673 · ownership.xml · nonDerivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,780 F2 · shares: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:50 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 13,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036673 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:09 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 33,210 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032412 · ownership.xml · derivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,210 Underlying: Common Stock · 33,210 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 3, 2026; (ii) 40% of the total shares on March 3, 2027; and (iii) 40% of the total shares on March 3, 2028. F2 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 3, 2026; (ii) 40% of the total shares on March 3, 2027; and (iii) 40% of the total shares on March 3, 2028. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:06 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 784 | $4.53 | $3,551.52 |
DisclosureSEC source: 0000950170-25-001339 · ownership.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,975 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| October 10, 2024 Filed Oct 11, 2024 21:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 7,465 | $11.39 | $85,026.35 |
DisclosureSEC source: 0001285550-24-000117 · wk-form4_1728680575.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,191 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 21:26 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 767 | $4.58 | $3,512.86 |
DisclosureSEC source: 0001285550-24-000091 · wk-form4_1719955601.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,656 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:40 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 65,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000076 · wk-form4_1716410428.xml · derivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,252 Underlying: Common Stock · 65,252 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 12, 2025; (ii) 40% of the total shares on March 12, 2026; and (iii) 40% of the total shares on March 12, 2027. F2 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on March 12, 2025; (ii) 40% of the total shares on March 12, 2026; and (iii) 40% of the total shares on March 12, 2027. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 6,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001285550-24-000026 · wk-form4_1709934073.xml · derivative · entry 3 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,654 Underlying: Common Stock · 6,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 3,463 | $6.24 | $21,609.12 |
DisclosureSEC source: 0001285550-24-000026 · wk-form4_1709934073.xml · nonDerivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,889 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 6,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000026 · wk-form4_1709934073.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2023 Filed Jan 4, 2024 01:52 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 590 | $5.77 | $3,404.30 |
DisclosureSEC source: 0001285550-24-000013 · wk-form4_1704333115.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,439 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first business day or last business day of the purchase period. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 18:44 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Tax withholdingCommon Stock | 7,603 | $5.04 | $38,319.12 |
DisclosureSEC source: 0001285550-23-000109 · wf-form4_169713626073950.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,849 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:47 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 552 | $6.15 | $3,394.80 |
DisclosureSEC source: 0001285550-23-000082 · wf-form4_168859363723465.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,452 F1 · price: The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2023 through June 30, 2023. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:51 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 34,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-23-000027 · wf-form4_167831225156484.xml · derivative · entry 2 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,567 Underlying: Common Stock · 34,567 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F3 · derivative.exercise_date: The restricted stock units vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:51 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 11,522 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001285550-23-000027 · wf-form4_167831225156484.xml · derivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,522 Underlying: Common Stock · 11,522 shares Expires 2033-03-06 F1 · derivative.exercise_date: The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. Read SEC document |
| October 10, 2022 Filed Oct 11, 2022 18:29 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 46,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-22-000069 · wf-form4_166551295326851.xml · nonDerivative · entry 1 SABRA MAZIN · CIK 0001947604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,900 F1 · shares: The shares are restricted stock and vest as follows: (i) one-third (1/3rd) on the first anniversary of the grant date; (ii) one-third (1/3rd) on the second anniversary of the grant date; and (iii) one-third (1/3rd) on the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.